Moderna

211,334

$59.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.58 (+0.99%) Today
-$0.15 (-0.25%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Moderna and other stocks, options, ETFs, and crypto commission-free!

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. Read More The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Employees
830
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
23.00B
Price-Earnings Ratio
Dividend Yield
Average Volume
17.26M
High Today
$60.73
Low Today
$57.10
Open Price
$58.49
Volume
9.97M
52 Week High
$87.00
52 Week Low
$11.54

Collections

MRNA News

Benzinga6h

Revisiting Coronavirus Vaccine Timelines: Moderna Denies Delay, Pfizer Advances Project Lightspeed And More

Shares of Moderna Inc (NASDAQ: MRNA), a frontrunner in the race for a coronavirus vaccine, tumbled Thursday afternoon after a STAT News report suggested there c
0
ReutersJul 2

How Moderna executives are cashing in on COVID-19 vaccine stock speculation

By Tom Bergin and Robin Respaut (Reuters) - Biotech firm Moderna Inc could reap tens of billions of dollars in sales and stock appreciation if it wins the race
0
ReutersJul 2

Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses

FILE PHOTO: A logo for Pfizer is displayed on a monitor on the floor at the NYSE in New York By Carl O'Donnell and Sujata Rao (Reuters) - Wall Street is movin
0

MRNA Earnings

-$0.44
-$0.29
-$0.15
$0.00
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
per share
Actual
Expected Aug 5, Pre-Market

You May Also Like

More MRNA News

CNBCJul 2

Moderna stock falls by as much as 9.4% after report says late-stage coronavirus vaccine trial delayed

However, the company is making changes to the trial plan, which has pushed back the expected start date, according to health-care publication STAT News , citing
0
Financial PostJul 2

Moderna shares slide after report of delay in COVID-19 vaccine trial

Shares of Moderna Inc fell 7% on Thursday after medical news site STAT reported a delay in a large trial testing the biotech’s potential coronavirus vaccine as
0
MarketWatchJul 2

Moderna's stock falls following report that the Phase 3 coronavirus vaccine trial has been delayed

Shares of Moderna Inc. MRNA, -6.00% declined 6.2% in trading on Thursday after people familiar with the matter told Stat News the start date for the company's P
0
New York TimesJul 2

Moderna's COVID-19 Vaccine Trial Delayed-STAT

(Reuters) - Shares of Moderna Inc fell 7% on Thursday after medical news site STAT reported a delay in a large trial testing the biotech's potential coronavirus
0
CNBCJul 2

Watch live: CDC director and other key U.S. health officials testify on coronavirus vaccine at Senate hearing

[The stream is slated to start at 10:00 a.m. ET. Please refresh the page if you do not see a player above at that time.] The U.S. Senate Appropriations Subcomm
0
ReutersJul 1

BRIEF-Elizabeth Tallett Joins Moderna's Board

July 1 (Reuters) - Moderna Inc: * ELIZABETH TALLETT JOINS MODERNA’S BOARD OF DIRECTORS * MODERNA INC - TALLETT WAS ALSO APPOINTED TO SERVE ON AUDIT COMMITTEE
0
MarketWatchJun 30

FDA issues rules for coronavirus vaccine developers

The Food and Drug Administration (FDA) issued new rules on Tuesday for the companies developing COVID-19 vaccines. "While the FDA is committed to help expedite
0
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.